![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BioMarin’s Hemophilia A Treatment Nabs Orphan Drug Status
BioMarin’s Hemophilia A Treatment Nabs Orphan Drug Status
The European Commission has granted orphan drug designation to BioMarin’s BMN 270, a gene therapy treatment for hemophilia A.
Earlier this month, the FDA awarded BMN 270 the same designation.
An AAV 5 factor VIII vector, BMN 270 is in a Phase 1/2 study evaluating the candidate in patients with severe hemophilia. The therapy is intended to restore factor VIII plasma concentrations.
Upcoming Events
-
21Oct